TNFRSF10B and glioblastoma: As glioblastoma cell lines predominately express TRAIL-R2, we selected a human monoclonal antibody specifically directed against TRAIL-R2 (Drozitumab) to target the TRAIL signaling pathway.19 To antagonize IAP proteins, we used the bivalent Smac mimetic BV6.9 Importantly, the addition of BV6 profoundly sensitized glioblastoma cells to Drozitumab-induced loss of cell viability, whereas treatment with Drozitumab alone had a moderate or minor effect on cell viability (Figure 1c and Supplementary Figure 1B).